A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.

Key Points

• Hemoglobin increased rapidly after pausing Alectinib, showing a positive outcome.
• The patient maintained stable disease during the switch to Lorlatinib, highlighting treatment efficacy.
• This case illustrates the potential benefits of switching therapies in managing hemolytic anemia.
• Future assessments may further clarify management strategies for lung cancer with hemolytic anemia.